BUTACLAMOL HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C25H31NO.ClH
Molecular Weight	397.981
Optical Activity	( + / - )
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.[H][C@]12C[C@](O)(CCN1C[C@]3([H])C4=C(CCC5=C3C2=CC=C5)C=CC=C4)C(C)(C)C

InChI

InChIKey=QZRUMKUMFJJARD-OMMJFLKZSA-N

InChI=1S/C25H31NO.ClH/c1-24(2,3)25(27)13-14-26-16-21-19-9-5-4-7-17(19)11-12-18-8-6-10-20(23(18)21)22(26)15-25;/h4-10,21-22,27H,11-16H2,1-3H3;1H/t21-,22-,25-;/m1./s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/355181

Butaclamol is an antipsychotic drug, which was studied for the treatment of schizophrenia. This drug has never marketed and now is used in research, because of its action as a dopamine receptor-blocking agent. Butaclamol consists of the two forms: (-)-butaclamol, an inactive drug and (+)-butaclamol, a potent neuroleptic drug.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine receptor 60 Target ID: CHEMBL2096905 Sources: https://www.ncbi.nlm.nih.gov/pubmed/908278	Blocker 537

Conditions

Condition	Modality	Targets	Highest Phase	Product
Schizophrenia 298 Sources: https://www.ncbi.nlm.nih.gov/pubmed/355181	Primary		Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor.	1990 Nov	2233697
Characterization of the human dopamine D3 receptor expressed in transfected cell lines.	1994 Jan 1	7907989
Lack of discrimination by agonists for D2 and D3 dopamine receptors.	1995 Jul	7576010
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.	1998 Aug 21	9760039

Patents

Sample Use Guides

In Vivo Use Guide

Maximum clinical response appeared to be at the 20-40 mg. dose level. Extrapyramidal signs occurred at all doses, but with greater severity at higher doses. Excessive daytime drowsiness occurred in all groups but with longer duration and greater intensity in the 20 mg. group.

Route of Administration: Intraperitoneal

In Vitro Use Guide

Unknown

Name

Type

Language

BUTACLAMOL HYDROCHLORIDE

Official Name

English

BUTACLAMOL HYDROCHLORIDE [USAN]

Common Name

English

AY 23028

Code

English

BUTACLAMOL HCL

Common Name

English

(±)-3.ALPHA.-TERT-BUTYL-2,3,4,4A.BETA.,8,9,13B.ALPHA.,14-OCTAHYDRO-1H-BENZO(6,7)-CYCLOHEPTA(1,2,3-DE)PYRIDO(2,1-A)ISOQUINOLIN-3-OL HYDROCHLORIDE

Common Name

English

1H-BENZO(6,7)CYCLOHEPTA(1,2,3-DE)-PYRIDO(2,1-A)ISOQUINOLIN-3-OL, 3-(1,1-DIMETHYLETHYL)-2,3,4,4A,8,9,13B,14-OCTAHYDRO-, HYDROCHLORIDE, (3.ALPHA.,4A.ALPHA.,13B.BETA.)-(±)-

Common Name

English

AY 23,028

Code

English

AY-23028

Code

English

1H-BENZO(6,7)CYCLOHEPTA(1,2,3-DE)-PYRIDO(2,1-A)ISOQUINOLIN-3-OL, 3-(1,1-DIMETHYLETHYL)-2,3,4,4A,8,9,13B,14-OCTAHYDRO-, (3.ALPHA.,4A.ALPHA.,13B.BETA.)-(±)-, HYDROCHLORIDE

Common Name

English

AY-23,028

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C66883